About the Company
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ODT News
VIRX Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product ...
SPRO Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections ...
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Aclaris Therapeutics Inc ACRS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Amicus Therapeutics Inc FOLD
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Aquestive Therapeutics, Inc. (AQST)
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Viking Therapeutics Inc (VKTX)
On Tuesday, Viking Therapeutics (NASDAQ:VKTX) saw its price target increased by an Oppenheimer analyst to $138 from the previous $116, while the stock's rating remains at... On Tuesday, Viking ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Loading the latest forecasts...